Information about the Mpox virus

The Mpox virus is a double-stranded DNA virus that is transmitted through close contact. In this article, you will learn how the virus is transmitted, what symptoms are typical and how you can protect yourself. In Germany, specific legal and health framework conditions apply, including the reporting obligations under the Infection Protection Act (IfSG) and the current epidemiological situation in the country.

Key facts at a glance

The Mpox virus belongs to the Poxviridae family, shows genetic variations in central and west African clades, and can be transmitted by close contact, especially via skin lesions. Close physical contact is required for transmission of the Mpox virus.

Diagnosis of Mpox infection is done through clinical examination and laboratory tests, while treatment focuses on symptom relief and the use of antiviral medications.

Vaccination against Mpox is an important part of prevention, especially for high-risk groups, and the disease is notifiable to protect public health and effectively control outbreaks.

What is the Mpox virus?

The Mpox virus is a double-stranded DNA virus that belongs to the Poxviridae family. It is closely related to the classical poxviruses and the cowpox viruses, meaning that it has similar genetic and structural features. This relationship also explains some of the clinical symptoms and the way the virus infects the human body. More information about the mpox virus is important to deepen the understanding of the disease.

There are two main genetic clades of Mpox virus: the Central African clade and the West African clade. These genetic variants differ in their geographical distribution and in some of their biological properties, which may influence disease courses and transmission dynamics.

Research into the Mpox virus is critical to developing effective treatment and prevention strategies. As knowledge of the virus's genetic and biological properties increases, scientists and health authorities can better respond to outbreaks and protect public health.

transmission of the Mpox virus

Transmission of the Mpox virus occurs mainly through close contact, including physical and sexual contact. Close physical contact is required for transmission of the Mpox virus. There is a particularly high risk when coming into contact with the contents of the blisters, as these are highly contagious and can easily cause transmission. Therefore, it is important to avoid direct contact with skin lesions and body fluids of infected people.

Places such as saunas, darkrooms or sex clubs pose an increased risk for Mpox transmission. The likelihood of transmission is increased during sexual contact, especially if the skin lesions are localized in these areas. These circumstances make it necessary for people who stay in such environments to be particularly careful and take appropriate protective measures.

Human-to-human transmission of the Mpox virus is an important factor in the spread of the virus. Comprehensive hygiene measures and awareness campaigns are needed to effectively prevent the spread. The role of vaccination as a preventive measure is also becoming increasingly important to break the chains of transmission and protect public health.

Symptoms and course of the disease

The typical symptoms of Mpox infection include fever, headache, muscle and back pain, and swollen lymph nodes. These symptoms are similar to those of many other viral infections, which can make diagnosis difficult. In addition to these general symptoms, those affected develop characteristic skin lesions that appear in different phases.

The skin lesions in Mpox go through several stages of development, starting with flat patches (maculae) that develop into raised nodules (papules) and finally turning into fluid-filled pustules. These pustules can be painful and eventually burst, forming crusts that fall off after a few weeks.

Symptoms tend to improve within a few weeks, although the duration of symptoms can vary. It usually takes two to four weeks for the skin lesions to heal completely and for the affected person to no longer be contagious. During this time, it is important to avoid close contact to prevent the spread of the virus.

incubation period and contagiousness

The incubation period for the Mpox virus is between five and 21 days, although shorter periods of one to four days have been observed in specific cases. This variability in the incubation period makes it difficult to predict the exact time between exposure and the onset of the first symptoms. This can also make it difficult to identify and trace chains of infection.

The virus can be transmitted from the onset of symptoms and remains contagious until the skin lesions heal, which usually takes two to four weeks. During this time, it is crucial that infected people remain isolated and avoid close contact to prevent further spread of the virus.

The contagiousness of Mpox depends greatly on the phase of the disease. The risk of transmission is particularly high during the phase in which the skin lesions are active and secrete fluid. Therefore, strict hygiene measures and early isolation of the person suffering from mpox are of utmost importance.

Diagnosis of the Mpox virus

Diagnosis of Mpox virus involves several steps, starting with clinical examination and ending with specialized laboratory tests. The clinical examination includes taking the medical history, physical examination and assessment of symptoms to suspect Mpox infection.

Laboratory diagnostic tests such as real-time PCR (rtPCR) and next generation sequencing (NGS) are crucial for confirming the diagnosis. Finally, differential diagnosis helps to rule out other diseases such as chickenpox or herpes zoster.

Clinical examination

The clinical examination is the first step in diagnosing Mpox infection. This involves taking the patient's medical history and performing a thorough physical examination. By evaluating symptoms such as fever, skin lesions and swollen lymph nodes, the doctor can make an initial suspected diagnosis.

It is particularly important to carefully inspect the skin lesions, as they have characteristic features that indicate Mpox infection. The clinical examination forms the basis for further diagnostic steps and the identification of suspected cases.

Laboratory diagnostics

Laboratory diagnostics of the Mpox virus include various methods that allow accurate identification of the virus. Real-time PCR (rtPCR) is a rapid and accurate method to detect Mpox virus DNA in samples. This method is particularly useful for detecting active infections and monitoring outbreaks.

Next-generation sequencing (NGS) enables a comprehensive analysis of the genome of the Mpox virus and its mutations. This technique offers deeper insights into the genetic structure of the virus and supports the development of targeted treatment and prevention strategies. In particular, clade Ib, which is associated with severe symptoms and higher mortality, can be better studied.

This technique provides deeper insights into the genetic structure of the virus and supports the development of targeted treatment and prevention strategies. The cases that have occurred in Europe since 2022 are due to the specific clade II, which provides important information on the epidemiological situation and transmission routes.

differential diagnosis

Differential diagnosis is an essential part of the diagnosis of Mpox, as many other diseases can have similar symptoms. Diseases that must be excluded in the differential diagnosis include:

• chickenpox
• Herpes zoster
• Syphilis
• Scarlet fever
• Lymphogranuloma venereum
• Herpes simplex
• other smallpox virus infections

An accurate differential diagnosis is crucial to initiate the correct treatment and prevent the spread of other infectious diseases. It also helps to avoid unnecessary treatment and to use health system resources efficiently.

therapy and treatment options

Treatment for Mpox is primarily aimed at relieving symptoms and preventing complications. Symptomatic treatments are crucial as severe cases of Mpox can lead to life-threatening complications. These include measures such as fever relief, pain management, and treatment of secondary bacterial infections.

Antiviral drugs such as tecovirimat and cidofovir are used to treat severe cases of Mpox. Tecovirimat is specifically approved for the treatment of orthopoxviruses, while cidofovir is used with careful monitoring of hydration due to its nephrotoxic effects. Brincidofovir offers an alternative with less nephrotoxicity, but may cause elevated liver enzyme levels.

For severely immunocompromised individuals, intravenous vaccinia immune globulin is recommended, especially when antiviral treatments are not effective. Patients with HIV and Mpox should start antiretroviral therapy immediately to improve immune function. It is important to monitor interactions of tecovirimat with other medications, as it may affect the concentrations of other drugs.

prevention and hygiene measures

Effective hygiene measures are crucial to prevent infection with the Mpox virus. Here are some important points to keep in mind:

1. Avoid contact with skin lesions, body fluids or contaminated objects of infected people.
2. Avoid close physical contact.
3. Regular cleaning of surfaces.
4. Wearing protective equipment in risky situations.

These measures help to minimize the risk of infection.

General hygiene measures

General hygiene measures include avoiding skin contact with infected people, especially touching rashes or wounds. People suspected of having Mpox infection should be isolated and their symptoms should be carefully monitored. Regular and frequent cleaning of surfaces is also an important measure to minimize the risk of infection.

Disposable gloves should be used according to the glove changing indications to maintain hygiene standards. These measures are simple to implement but extremely effective in preventing further spread of the virus.

Measures in case of suspected infection

If Mpox infection is suspected, immediate action is needed to prevent the virus from spreading. A person with clade I infection should be isolated for up to four weeks to ensure that the virus is not spread further. During this time, affected individuals should closely monitor their symptoms and avoid close contacts.

Here is the text with the integrated keyword: “If you find yourself in a difficult situation, you should be aware that it is important to keep a cool head while trapped.”

If Mpox infection is suspected, immediate action is needed to prevent the spread of the virus. Here are the recommended steps:

1. A person with clade I infection should be isolated for up to four weeks to ensure that the virus is not spread further.
2. During this time, affected individuals should closely monitor their symptoms.
3. Close contact should be avoided.

In addition to quarantine measures, situational prevention measures such as specific information, education, advice and, if necessary, vaccinations are necessary. These measures help to break the chains of infection and prevent the spread of the virus in the community.

For more information, see our FAQ section, which answers frequently asked questions about Mpox and its protection measures.

dealing with contact persons

How people who have had close contact with an infected person are treated is also very important. The risk of infection for household members who were not directly exposed is low. Nevertheless, close physical contact should be avoided and preventive hygiene measures should be strictly observed to minimize the risks of contact.

This also includes regular cleaning of surfaces and washing of clothing, bedding and towels that have been in contact with the infected person.

vaccination against Mpox

Vaccination against Mpox plays a crucial role in preventing and controlling outbreaks. In the United States, the vaccine Jynneos and in Canada Imvamune are approved for the prevention of Mpox. These vaccines are approved for use from age 18 and provide effective protection against the virus.

The Imvanex vaccine, a third-generation vaccine, also protects against Mpox and is available in many countries. For people without previous smallpox vaccination, two doses of the vaccine, given at least 28 days apart, are required to ensure adequate protection. These vaccinations help to significantly reduce the risk of disease from Mpox.

Preventive measures against Mpox include not only vaccinations but also strict hygiene measures to minimize the risk of transmission. Vaccination is especially recommended for people in high-risk groups and for medical personnel who regularly come into contact with potentially infected people or materials. The widespread use of vaccinations can effectively contain the spread of the virus.

Both the Robert Koch Institute and international health authorities emphasize the importance of vaccination as a preventive measure. These vaccinations not only help prevent individual infections, but also protect the wider population and help prevent future outbreaks.

Legal basis and reporting obligation

Mpox is a notifiable disease, which means that if an infection is suspected, the responsible health authority must be contacted immediately. This reporting requirement is crucial to monitor the spread of the virus and take appropriate measures to contain it. Managers of community facilities must notify the health authority immediately if an illness or suspected illness occurs in people.

Reports must be made to the health authority. This must be done no later than 24 hours after knowledge of the disease. This rapid reporting enables the health authorities to react quickly and prevent potential outbreaks. The restriction of activities in community facilities will continue until a medical opinion indicates that there is no longer any risk of further spread.

Compliance with these legal requirements will help protect public health and effectively contain the spread of the Mpox virus. It is important that everyone involved - from health authorities to affected individuals - work together to prevent the spread of the virus.

International situation and outbreak events

Until 2022, the Mpox virus was mainly distributed in West and Central Africa. The first human cases of Mpox were identified in 1970, and since then the virus has caused regular outbreaks in these regions. In the current global outbreak, clade IIb is circulating, which has been detected in several countries outside Africa.

Since 2022, the majority of cases of Mpox have been mild to moderate, making it easier to treat and manage the disease. Nevertheless, surveillance and prevention remain crucial, especially in regions with a high risk of infection. The Democratic Republic of Congo and neighboring countries are particularly affected by Mpox, where the virus is endemic and regularly leads to outbreaks. The current state of the Mpox epidemic shows that infection rates must continue to be monitored in order to adapt health recommendations.

The first cases of Mpox in Austria occurred in May 2022, further highlighting the international spread of the virus. The WHO declared a public health emergency of international concern regarding Mpox in August 2024 to mobilize the international community to increase cooperation and response to the virus. This declaration underscores the importance of global efforts to contain the virus.

High-risk groups such as children, immunocompromised people and the elderly are at risk of more severe disease progression from Mpox, which highlights the need for preventive measures and rapid medical intervention. The international community must remain vigilant and work together to prevent the spread of the Mpox virus.

Mpox: Current Research and Studies

Current research and studies are focused on developing vaccines and treatments against Mpox. Scientists are working hard to develop effective vaccines that provide long-term protection. There are also studies on human-to-human transmission of Mpox and the role of contacts in spreading the disease. In addition, research is being conducted to better understand the genetic properties of Mpox viruses and to study their impact on human health. These findings are crucial to developing effective prevention and treatment strategies.

Mpox: International Cooperation

International cooperation plays an important role in the fight against Mpox. The World Health Organization (WHO) and other international organizations are working closely with affected countries to prevent the spread of Mpox and to combat the disease. There are also international research projects focused on developing vaccines and treatments. These global efforts are critical to protecting public health and preventing future outbreaks.

advice and special diagnostics

The Robert Koch Institute (RKI) offers advice and special diagnostics for Mpox. The RKI has a consultancy laboratory for poxviruses that offers special diagnostic methods to detect Mpox viruses. These specialised tests are crucial for accurately identifying the virus and monitoring outbreaks. In addition, the RKI offers advice for doctors and other health professionals to support the diagnosis and treatment of Mpox. This support is particularly important to prevent the spread of the virus and to ensure the best possible care for patients.

Summary: Key takeaways about intuitive eating

In conclusion, Mpox virus is a serious public health threat that requires a comprehensive and coordinated response. Transmission of the virus occurs mainly through close contact, and symptoms can vary from mild to severe. Early diagnosis and treatment are crucial to avoid complications and prevent the spread of the virus.

Prevention through hygiene measures and vaccination is of paramount importance to prevent future outbreaks. Legal reporting requirements and international efforts to combat the virus are also crucial factors to protect public health and contain the virus.

Finally, it is important to emphasize that cooperation and awareness among communities worldwide are crucial to stop the spread of the Mpox virus. Each individual can help ensure the health and safety of everyone through preventive measures and compliance with health guidelines.

Frequently Asked Questions

What is the Mpox virus?

The Mpox virus is a double-stranded DNA virus from the Poxviridae family and is closely related to the classic poxviruses. It is important to be informed about the characteristics and risks of this virus.

pathogens and occurrence

Mpox is caused by monkeypox virus (MPXV), an enveloped DNA virus in the genus Orthopoxvirus. The virus is closely related to the classic human poxviruses (variola) and the zoonotic cowpox viruses. Mpox viruses are common in rodents in West and Central Africa. In humans, Mpox was first identified in a 1970-month-old boy in the Democratic Republic of Congo in 9. This discovery marked the beginning of scientific research into the virus and its effects on human health.

Mpox clade I

Mpox clade I is one of the two genetic groups into which Mpox viruses are classified. This clade is distributed in Central Africa and is caused by viruses of subclades Ia and Ib. Mpox clade I is responsible for most cases of Mpox in Africa and is also observed in other parts of the world. The genetic differences between the clades may influence disease courses and transmission dynamics, which underlines the importance of research and monitoring this clade.

How is the Mpox virus transmitted?**?

The Mpox virus is transmitted mainly through close physical contact, including sexual contact, as well as through contact with skin lesions and body fluids of infected persons.

What symptoms does an Mpox infection cause?**?

An Mpox infection typically causes symptoms such as fever, headache, muscle and back pain, and swollen lymph nodes. In addition, characteristic skin lesions occur that go through different phases.

Is there a vaccination against Mpox?**?

Yes, there are vaccines such as Jynneos and Imvamune to prevent Mpox. People without previous smallpox vaccination will need two doses at least 28 days apart.

What legal reporting obligations are there in the case of an Mpox infection?**?

In the case of an Mpox infection, there is a legal reporting obligation that requires the immediate reporting of suspected cases to the responsible health authority within 24 hours.